Dwanaście powodów, dla których warto stosować amlodipinę Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2014
Słowa kluczowe:
amlodipina, nadciśnienie tętnicze, ryzyko sercowo-naczyniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Amlodipina zajmuje istotne miejsce we współczesnej farmakoterapii chorób układu sercowo-naczyniowego. Cechuje ją potwierdzona w wielu dużych, randomizowanych badaniach klinicznych skuteczność hipotensyjna w monoterapii lub w skojarzeniu z innymi lekami przeciwnadciśnieniowymi. Amlodipina korzystnie wpływa na częstość występowania powikłań sercowo- naczyniowych, a długi czas jej działania zapewnia całodobową kontrolę ciśnienia tętniczego. Cechuje się także wysoką selektywnością względem naczyń obwodowych oraz korzystnym oddziaływaniem na krążenie wieńcowe. Duże znaczenie ma również neutralny profil metaboliczny, co jest istotne zwłaszcza u chorych na nadciśnienie tętnicze współistniejące z otyłością, zaburzoną przemianą lipidową lub cukrzycą.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2014). Dwanaście powodów, dla których warto stosować amlodipinę . Medycyna Faktów , 7(4(25), 41-47. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2335
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Toyo-oka T., Naylor W.G.: Third generation calcium entry blockers. Blood Press 1996; 5(4): 206-208.
2. Januszewicz A., Kabat M.: Amlodypina – współczesne miejsce w terapii nadciśnienia tętniczego. Probl. Terapii Monitor. 2001; 12(supl. 2): 46-50.
3. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Nadciśnienie Tętnicze 2006; 10(3): 235-250.
4. Ferrari P., Giachino D., Weidmann P. et al.: Unaltered insulin sensitivity during calcium channel blockade with amlodipine. Eur. J. Clin. Pharmacol. 1993; 44: 457-462.
5. de Courten M., Ferrari P., Schneider M. et al.: Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur. J. Clin. Pharmacol. 1993; 44: 457-462.
6. Zanetti-Elshater F., Pingitore R., Beretta-Piccoli C. et al.: Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am. J. Hypertens. 1994; 7: 36-45.
7. Seccia M., Vulpis V., Ricci S. et al.: Antihypertensive and metabolic effects of amlodipine in patients with non-insulin-dependent diabetes mellitus. Clin. Drug Invest. 1995; 9: 16-21.
8. Picca M., Bisceglia J., Zocca A. et al.: Effects of enalapryl and amlodipine on left ventricular hypertrophy and function in essential hypertension. Clin. Drug Invest. 1997; 13(supl. 1): 29-35.
9. Beltman F.W., Heesen W.F., Smit A.J. et al.: Effects of amlodipine and lizynopryl on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press 1998; 7: 109-117.
10. Agabiti-Rosei E., Muiesan M.L., Rizzoni D. et al.: Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J. Cardiovasc. Pharmacol. 1994; 24(supl. A): S37-43.
11. Jennings G.L., Wong J.: Assessment of hypertensive organ damage. W: Handbook of Hypertension, Hansen and Birkenhager (eds.). Wong J. Elsevier 1997.
12. Kramsch D.M., Sharma R.C.: Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J. Hum. Hypertens. 1995; 9(supl. 1): S3-9.
13. Mason R.P., Kubant R., Heeba G. et al.: Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008; 25: 1798-1806.
14. Stanton A.V., Chapman J.N., Mayet J. et al.: Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clin. Sci. (Lond). 2001; 101: 455-464.
15. Tulenko T.N., Sumner A.E., Chen M.: The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am. Heart J. 2001; 141(supl. 2): S1-11.
16. Zhang X., Hintze T.H.: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
17. Berkels R., Taubert D., Bartels H. et al.: Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004; 70: 39-45.
18. Schaaf M.R., Hené R.J., Floor M. et al.: Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 1995; 25: 77-81.
19. Jørgensen B., Simonsen S., Endresen K. et al.: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000; 35: 592-599.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
21. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
22. Jamerson K., Weber M.A., Bakris G.L. et al. for the ACCOMPLISH Trial Investigators: Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N. Engl. J. Med. 2008; 359: 2417-2428.
23. Liebson P.R., Grandits G.A., Dianzumba S. et al.: Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91(3): 698-706.
24. Williams B., Lacy P.S., Thom S.M. et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-1225.
25. Deanfield J.E., Detry J.M., Lichtlen P.R. et al.: Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J. Am. Coll. Cardiol. 1994; 24(6): 1460-1467.
26. Nissen S.E., Tuzcu E.M., Libby P. et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-2225.
27. Neuberg G.W., Miller A.B., O’Connor C.M. et al.; PRAISE Investigators: Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am. Heart J. 2002; 144(1): 31-38.
28. Wright J.T. Jr, Bakris G., Greene T. et al.: African-American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
29. Pitt B., Byington R.P., Furberg C.D. et al.; PREVENT Investigators: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-1510.
30. Packer M., O’Connor M., Ghali J.K. et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. 1996; 335: 1107-1114.
31. Perna G.P., Valle G., Cianfrone N. et al.: Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure. Clin. Drug Invest. 1998; 16: 289-296.
32. Udelson J.E., DeAbate C.A., Berk M. et al.: Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am. Heart J. 2000; 139: 503-510.
33. McMurray J.J., Adamopoulos S., Anker S.D. et al.; ESC Committee for Practice Guidelines: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012; 33(14): 1787-1847.
34. Staessen J.A., Thijs L., Celis H. et al.; Systolic Hypertension in Europe Trial Investigators (the Syst-Eur Trial): Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients – evidence from the Systolic Hypertension in Europe Trial. S. Afr. Med. J. 2001; 91(12): 1060-1068.
35. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-2219.
2. Januszewicz A., Kabat M.: Amlodypina – współczesne miejsce w terapii nadciśnienia tętniczego. Probl. Terapii Monitor. 2001; 12(supl. 2): 46-50.
3. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Nadciśnienie Tętnicze 2006; 10(3): 235-250.
4. Ferrari P., Giachino D., Weidmann P. et al.: Unaltered insulin sensitivity during calcium channel blockade with amlodipine. Eur. J. Clin. Pharmacol. 1993; 44: 457-462.
5. de Courten M., Ferrari P., Schneider M. et al.: Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur. J. Clin. Pharmacol. 1993; 44: 457-462.
6. Zanetti-Elshater F., Pingitore R., Beretta-Piccoli C. et al.: Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am. J. Hypertens. 1994; 7: 36-45.
7. Seccia M., Vulpis V., Ricci S. et al.: Antihypertensive and metabolic effects of amlodipine in patients with non-insulin-dependent diabetes mellitus. Clin. Drug Invest. 1995; 9: 16-21.
8. Picca M., Bisceglia J., Zocca A. et al.: Effects of enalapryl and amlodipine on left ventricular hypertrophy and function in essential hypertension. Clin. Drug Invest. 1997; 13(supl. 1): 29-35.
9. Beltman F.W., Heesen W.F., Smit A.J. et al.: Effects of amlodipine and lizynopryl on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press 1998; 7: 109-117.
10. Agabiti-Rosei E., Muiesan M.L., Rizzoni D. et al.: Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J. Cardiovasc. Pharmacol. 1994; 24(supl. A): S37-43.
11. Jennings G.L., Wong J.: Assessment of hypertensive organ damage. W: Handbook of Hypertension, Hansen and Birkenhager (eds.). Wong J. Elsevier 1997.
12. Kramsch D.M., Sharma R.C.: Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J. Hum. Hypertens. 1995; 9(supl. 1): S3-9.
13. Mason R.P., Kubant R., Heeba G. et al.: Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008; 25: 1798-1806.
14. Stanton A.V., Chapman J.N., Mayet J. et al.: Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clin. Sci. (Lond). 2001; 101: 455-464.
15. Tulenko T.N., Sumner A.E., Chen M.: The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am. Heart J. 2001; 141(supl. 2): S1-11.
16. Zhang X., Hintze T.H.: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
17. Berkels R., Taubert D., Bartels H. et al.: Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004; 70: 39-45.
18. Schaaf M.R., Hené R.J., Floor M. et al.: Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 1995; 25: 77-81.
19. Jørgensen B., Simonsen S., Endresen K. et al.: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000; 35: 592-599.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
21. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
22. Jamerson K., Weber M.A., Bakris G.L. et al. for the ACCOMPLISH Trial Investigators: Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N. Engl. J. Med. 2008; 359: 2417-2428.
23. Liebson P.R., Grandits G.A., Dianzumba S. et al.: Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91(3): 698-706.
24. Williams B., Lacy P.S., Thom S.M. et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-1225.
25. Deanfield J.E., Detry J.M., Lichtlen P.R. et al.: Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J. Am. Coll. Cardiol. 1994; 24(6): 1460-1467.
26. Nissen S.E., Tuzcu E.M., Libby P. et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-2225.
27. Neuberg G.W., Miller A.B., O’Connor C.M. et al.; PRAISE Investigators: Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am. Heart J. 2002; 144(1): 31-38.
28. Wright J.T. Jr, Bakris G., Greene T. et al.: African-American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
29. Pitt B., Byington R.P., Furberg C.D. et al.; PREVENT Investigators: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-1510.
30. Packer M., O’Connor M., Ghali J.K. et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. 1996; 335: 1107-1114.
31. Perna G.P., Valle G., Cianfrone N. et al.: Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure. Clin. Drug Invest. 1998; 16: 289-296.
32. Udelson J.E., DeAbate C.A., Berk M. et al.: Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am. Heart J. 2000; 139: 503-510.
33. McMurray J.J., Adamopoulos S., Anker S.D. et al.; ESC Committee for Practice Guidelines: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012; 33(14): 1787-1847.
34. Staessen J.A., Thijs L., Celis H. et al.; Systolic Hypertension in Europe Trial Investigators (the Syst-Eur Trial): Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients – evidence from the Systolic Hypertension in Europe Trial. S. Afr. Med. J. 2001; 91(12): 1060-1068.
35. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-2219.